Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2006-12-05
2010-02-23
Ouspenski, Ilia (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C514S012200
Reexamination Certificate
active
07666991
ABSTRACT:
The present invention relates, in part, to methods and compositions for needleless delivery of antibodies to a subject. The present invention also relates, in part, to methods for needleless delivery of fusion proteins comprising a bioactive molecule and an antibody fragment to subject. In one aspect, the methods and compositions involve administering to the subject a delivery construct comprising a carrier construct non-covalently bound to the antibody or fusion protein to be delivered, wherein the carrier construct comprises a receptor-binding domain, a transcytosis domain, and an antibody-binding domain to which the antibody or the antibody fragment of the fusion protein non-covalently binds.
REFERENCES:
patent: 4677070 (1987-06-01), Larrick et al.
patent: 5328984 (1994-07-01), Pastan et al.
patent: 5374620 (1994-12-01), Clark et al.
patent: 5458878 (1995-10-01), Pastan et al.
patent: 5512658 (1996-04-01), Pastan et al.
patent: 5541287 (1996-07-01), Yau et al.
patent: 5602095 (1997-02-01), Pastan et al.
patent: 5668255 (1997-09-01), Murphy
patent: 5696077 (1997-12-01), Johnson et al.
patent: 5696237 (1997-12-01), FitzGerald et al.
patent: 5854044 (1998-12-01), Pastan et al.
patent: 5863745 (1999-01-01), FitzGerald et al.
patent: 5965406 (1999-10-01), Murphy
patent: 6022950 (2000-02-01), Murphy
patent: 6022966 (2000-02-01), Gustavson et al.
patent: 6051405 (2000-04-01), FitzGerald et al.
patent: 6072041 (2000-06-01), Davis et al.
patent: 6086900 (2000-07-01), Draper
patent: 6251392 (2001-06-01), Hein et al.
patent: 6391280 (2002-05-01), Hiatt et al.
patent: 6440419 (2002-08-01), Hein et al.
patent: 6485726 (2002-11-01), Blumberg et al.
patent: 6488926 (2002-12-01), Khan et al.
patent: 6673574 (2004-01-01), Stern et al.
patent: 2002/0106370 (2002-08-01), Cardy
patent: 2003/0054012 (2003-03-01), Fitzgerald et al.
patent: 2004/0001801 (2004-01-01), Madison et al.
patent: 2004/0071731 (2004-04-01), Fitzgerald
patent: 2004/0209330 (2004-10-01), Xu et al.
patent: 2004/0228831 (2004-11-01), Belinka et al.
patent: 2005/0079171 (2005-04-01), Fitzgerald et al.
patent: 2006/0104993 (2006-05-01), Mrsny
patent: 2006/0110409 (2006-05-01), Shone et al.
patent: 2006/0153798 (2006-07-01), Mrsny
patent: 2007/0003578 (2007-01-01), Fitzgerald
patent: 2007/0141070 (2007-06-01), Mrsny
patent: 2007/0148131 (2007-06-01), Mrsny
patent: 2009/0092660 (2009-04-01), Mrsny
patent: WO 86/06635 (1986-11-01), None
patent: WO 95/07297 (1995-03-01), None
patent: WO 98/20135 (1998-05-01), None
patent: WO 98/42876 (1998-10-01), None
patent: WO 00/46246 (2000-08-01), None
patent: WO 01/30392 (2001-05-01), None
patent: WO 01/31020 (2001-05-01), None
patent: WO 03/084470 (2003-10-01), None
patent: WO 2004/043484 (2004-05-01), None
patent: WO 2006/044205 (2006-04-01), None
ISA/US PCT International Search Report dated Jul. 8, 2008, for International Application No. PCT/US2006/46510, filed Dec. 5, 2006.
U.S. Appl. No. 09/462,682, filed Apr. 28, 2000, Fitzgerald.
U.S. Appl. No. 10/110,880, filed Apr. 16, 2002, Fitzgerald et al.
U.S. Appl. No. 11/664,786, filed Apr. 3, 2007, Mrsny.
U.S. Appl. No. 11/664,787, filed Apr. 3, 2007, Mrsny.
U.S.P.T.O. Non-Final Office Action, dated Sep. 20, 2007, in U.S. Appl. No. 11/244,349, filed Oct. 4, 2005.
U.S.P.T.O. Non-Final Office Action, dated Jul. 22, 2008, in U.S. Appl. No. 11/244,349, filed Oct. 4, 2005.
U.S.P.T.O. Non-Final Office Action, dated Mar. 14, 2006, in U.S. Appl. No. 10/110,880, filed Apr. 16, 2002.
U.S.P.T.O. Non-Final Office Action, dated Feb. 23, 2007, in U.S. Appl. No. 10/110,880, filed Apr. 16, 2002.
PCT International Search Report, dated May 11, 2006, in International Application No. PCT/US2005/35803, filed Oct. 4, 2005.
PCT International Search Report, dated Jan. 10, 2002, in International Application No. PCT/US2000/29080, filed Oct. 18, 2000.
PCT International Search Report, dated Jun. 28, 2007, in International Application No. PCT/US2006/46511, filed Dec. 5, 2006.
PCT International Search Report, dated Aug. 18, 2008, in International Application No. PCT/US2007/17795, filed Aug. 9, 2007.
PCT International Search Report, dated May 21, 2008, in International Application No. PCT/US2007/06590, filed Mar. 15, 2007.
www.cancerweb.ncl.ac.uk/cgi-bin/omd?elastase, Nov. 18, 1997, downloaded Sep. 10, 2007.
www.cancerweb.ncl.ac.uk/cgi-bin/omd?leukocyte+elastase, Dec. 12, 1998, downloaded Sep. 10, 2007.
Allured et al., 1986, “Structure of Exotoxin A of Pseudomonas Aeruginosa at Angstrom Resolution,” Proc. Natl. Acad. Sci., vol. 83:1320-1324.
Andreasen et al., 1994, “Receptor-Mediated Endocytosis of Plasminogen Activators and Activator/Inhibitor Complexes,” FEBS Letters, vol. 338(3):239-245.
Backer et al., 2002, “Molecular Vehicles for Targeted Drug Delivery,” Bioconjugate Chem., vol. 13:462-467.
Cavallaro et al., 1995, “Targeting Plant Toxins to the Urokinase and α-2-Macroglobulin Receptors,” Semin Cancer Biol., vol. 6(5):269-278.
Cerletti, A. et al., 2000, “Endocytosis and Transcytosis of an Immunoliposome-Based Brain Drug Discovery,” J. Drug Targeting, vol. 8(6):435-436.
Daugherty et al., 2000, “Epithelial Application of Pseudomonas Aeruginosa Exotoxin A Results in a Selective Targeting to Cells in the Liver, Spleen and Lymph Node,” J. Controlled Release, vol. 65(1-2):297-302.
Fitzgerald et al., 1998, “Characterization of V3 Loop-Pseudonomas Exotoxin Chimeras. Candidate Vaccines for Human Immunodeficiency Virus-1,” J. Biol. Chem., vol. 273(16):9951-9958.
Florence, A.T. et al., 2001, “Transcytosis of Nanoparticle and Dendrimer Delivery Systems: Evolving Vistas,” Advanced Drug Delivery, vol. 40(Supp. I):569-589.
Foraker, A.B. et al., 2003, “Microfacbricated Porous Silicon Particles Enhance Paracellular Delivery of Insulin Across Intestinal Caco-2 Cell Monolayers,” Pharm. Res., vol. 20(1):110-116.
Gray et al., 1984, “Cloning, Nucleotide Sequence, and Expression in Escherichia Coli of the Exotoxin A Structural Gene of Pseudomonas Aeruginosa,” PNAS, vol. 81:2645-2649.
Haltner, E. et al., 1997, “Lectins and Bacterial Invasion Factors for Controlling Endo- and Transcytosis of Bioadhesive Drug Carrier Systems,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 44(1):3-13.
Kreuter, J. et al., 2002, Apolipoprotein-Mediated Transport of Nanoparticle-Bound Drugs Across the Blood-Brain Barrier, J. Drug. Targeting, vol. 10(4):317-325.
Herz and Strickland, 2001, “LRP: A Multifunctional Scavenger and Signaling Recpetor,” J. Clin. Invest., vol. 108(6):779-784.
Kavimandan, N.J. et al., 2006, “Novel Delivery System Based on Complexation Hydrogels as Delivery Vehicles for Insulin-Transferrin Conjugates,” Biomaterials, vol. 27(20):3846-3854.
Kounnas et al., 1992, “The Alpha 2-Macroglobulin Receptor/Low Density Lipoprotein Receptor-Related Protein Binds and Internalizes Pseudomonas Exotoxin A.” J. Biol. Chem., vol. 267:12420-12423.
Mayer et al., 2003, “Furin Interacts with proMT1-MMP and Integrin αV at Specialized Domains of Renal Cell Plasma Membrane,” J. Cell Sci., vol. 116:1763-1773.
Maziere et al., 1992, “Processing and Characterization of the Low Density Lipoprotein Receptor in the Human Colonic Carcinoma Cell Subclone HT29-18: A Potential Pathway for Delivering Therapeutic Drugs and Genes,” Biosci. Rep., vol. 12(6):483-494.
Melman et al., 2001, “High Affinity Binding of Receptor-Associated Protein to Heparin and Low Density Lipoprotein Receptor-Related Protein Requires Similar Basic Amino Acid Sequence Motifs,” J. Biol. Chem., vol. 276(31):29338-29346.
Mikulska et al., 2000, “Cloning and Analysis of the Gene Encoding the Human Neonatal Fc Receptor,” Eur. J. Immunogenet., vol. 27(4):231-240.
Mrsny et al., 1999, “Mucosal Administration of a Chimera Composed of Pseudomonas Exotoxin and the gp 120 V3 Loop Sequence of HIV-1 Induces Both Salivary and Serum Antibody Responses,” Vaccine, vol. 17(11-12):1425-14
Jones Day
Ouspenski Ilia
Trinity Biosystems, Inc.
LandOfFree
Compositions for needleless delivery of antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for needleless delivery of antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for needleless delivery of antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4189459